Please assess the completion status of the following clinical trial:

Trial Title: A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of stage 4 neuroblastoma diagnosed in accordance with the International Neuroblastoma Staging System: either (a) histologic confirmation which may involve immunohistochemical, ultrastructural, and/or cytogenetic studies, or (b) elevated urinary catecholamines plus tumor cells/clumps in the bone marrow.~* Have evaluable disease or biopsy-proven stable disease in BM by histology or MIBG scan with MIBG-positive disease confined to the bone or bone marrow, plus urine catecholamine results, documented \>3 weeks after conventional chemotherapy or \>6 weeks after stem-cell transplantation. CT, MRI, or bone scan (if necessary) can be done at 2-3 weeks after conventional chemotherapy confirming that the chemotherapy, radiotherapy, and ABMT are not realistic curative options.~* Be between 18 months to 13 years old at diagnosis.~* Have recovered to grade 2 or better toxicities since their prior therapy.~* Must, if female of childbearing potential, be willing to use two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening and monthly thereafter through the first four cycles of treatment.~* Have a performance score of at least 60 from Lansky Play Performance Scale if aged up to 16 years or at least 60 from Karnofsky Scale if aged more than 16 years.~* Have voluntarily agreed to participate.~Exclusion Criteria:~* Have measurable disease ≥ 1 cm assessed by CT or MRI.~* Have progressive disease (any new lesion; increase of any measurable lesion by \>25%; or previous negative marrow positive for tumor).~* Have disease detectable in CNS (confirmed by CT or MRI of the brain at screening or within 8 weeks of randomization).~* Be receiving alternative therapy for the treatment of neuroblastoma, e.g. radiotherapy or chemotherapy within 3 weeks of randomization.~* Require additional therapy (such as radiotherapy) during the first two treatment cycles.~* Have detectable human anti-mouse antibody titers at screening.~* Have received prior anti-GD2 investigational therapies.~* Have a history of allergies to mouse proteins.~* Have an active infection requiring IV infusion of antibiotics.~* Be currently receiving long-term chronic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- ARM I (Type: EXPERIMENTAL): Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- ARM II (Type: ACTIVE_COMPARATOR): Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

Based on this trial design, predict the completion outcome and termination type (if applicable).